Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Aastrom Biosciences Inc Announces CEO Tim M. Mayleben Plan To Retire
Aastrom Biosciences Inc announced that Tim M. Mayleben has decided to retire from his position as the Company's president and Chief Executive Officer (CEO) once the Company has hired his successor. As a result of his decision, the Aastrom board of directors has initiated a search for a new CEO. In addition to remaining as president and CEO until a successor is found, Mr. Mayleben will continue to serve as a member of the board of directors after the transition.
Latest Developments for Aastrom Biosciences Inc
- Aastrom Biosciences Inc Announces Strategic Change In Research And Development Programs; Executes Corporate Restructuring
- Aastrom Biosciences Inc Names Dominick C. Colangelo President And CEO
- Aastrom Biosciences Inc Announces Management Change-Form 8-K
- Aastrom Biosciences, Inc. Announces Common Stock Exchange For December 2010 Warrants
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this
Follow Reuters